Clover Biopharmaceuticals
Research-based biotechnology company focused on discovering, developing and commercializing transformative biologic therapies.
Launch date
Employees
Market cap
€29.6m
Enterprise valuation
(€22m) (Public information from Sep 2024)
Share price
HKD0.225 2197.HK
Chengdu Sichuan (HQ)
Financials
Estimates*
| CNY | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | 39.3m | 15.9b | 18.5b |
| % growth | - | - | - | - | - | 40474 % | 16 % |
| EBITDA | (35.9m) | (904m) | (6.0b) | (2.4b) | 1.7b | 366m | 474m |
| % EBITDA margin | - | - | - | - | 4369 % | 2 % | 3 % |
| Profit | (48.6m) | (913m) | (6.0b) | (2.5b) | (139m) | - | - |
| % profit margin | - | - | - | - | (353 %) | - | - |
| EV / revenue | - | - | - | - | 7.9x | -0.1x | -0.1x |
| EV / EBITDA | - | - | -1.7x | -0.7x | 0.2x | -4.1x | -3.9x |
| R&D budget | 45.8m | 228m | 1.8b | 1.5b | 650m | - | - |
| R&D % of revenue | - | - | - | - | 1656 % | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | JPY62.8m | Series A | |
$43.3m | Series B | ||
* | N/A | Acquisition | |
$24.0m | Series B | ||
$230m | Series C | ||
| N/A | $260m | IPO | |
* | $38.9m | Grant | |
| Total Funding | €306m | ||
Recent News about Clover Biopharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.